Product Description
PRA023, is a monoclonal antibody against cytokine TL1A, a target associated with both intestinal inflammation and fibrosis. (Sourced from: https://prometheusbiosciences.com/pipeline/pra023/)
Mechanisms of Action: TL1A Antagonist
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous,Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, Canada, Czech Republic, France, Georgia, Germany, Hungary, Israel, Italy, Netherlands, Norway, Poland, Spain, Switzerland, United Kingdom, United States
Active Clinical Trial Count: 9
Highest Development Phases
Phase 3: Colitis, Ulcerative
Phase 2: Crohn Disease|Lung Diseases, Interstitial|Scleroderma, Diffuse|Scleroderma, General|Scleroderma, Systemic
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| MK-7240-001 | P3 |
Recruiting |
Colitis, Ulcerative |
2026-11-21 |
33% |
| ATHENA-SSc-ILD | P2 |
Recruiting |
Scleroderma, Diffuse|Scleroderma, Systemic|Scleroderma, General|Lung Diseases, Interstitial |
2025-12-19 |
46% |
| 2021-000092-37 | P2 |
Active, not recruiting |
Crohn Disease |
2025-10-14 |
|
| The ATHENA-SSc-ILD Study. | P2 |
Active, not recruiting |
Scleroderma, General |
2025-06-09 |